Literature DB >> 688725

Time-course of interaction between carbamazepine and clonazepam in normal man.

A A Lai, R H Levy, R E Cutler.   

Abstract

The applicability of a pharmacokinetic model for drug interactions by enzyme induction was tested by chronic dosing situation using carbamazepine (Tegretol) as the inducer and clonazepam (Clonopin) as the drug affected. Seven healthy subjects received one 1.0 mg clonazepam tablet once a day for 29 days and one 200 mg carbamazepine tablet once a day from days 8 to 29. Plasma levels of clonazepam were measured by electron-capture gas-liquid chromatography and those of carbamazepine and its epoxide metabolite by gas chromatographic-chemical ionization-mass spectrometry. Clonazepam plasma levels reached an initial steady-state by day 7 and declined to a lower steady-state over 5 to 15 days after additions of carbamazepine. The decrease in clonazepam levels ranged between 19% and 37%. Autoinduction of carbamazepine metabolism was also evident. Urinary excretion of D-glucaric acid increased 2- to 4-fold following carbamazepine administration (p less than 0.005). This increase provided additional evidence that the present interaction was due to enzyme induction. Experimental clonazepam levels were fitted to an induction pharmacokinetic model for multiple dosing with an exponentially increasing clearance. Induced half-lives of clonazepam (mean = 22.5 +/- 11.5 hr) were shorter (p less than 0.005) than control values (32.1 +/- 16.6 hr). Apparent enzyme(s) turnover half-lives ranged between 1 and 6 days.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 688725     DOI: 10.1002/cpt1978243316

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  30 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.

Authors:  Sara K Quinney; Xin Zhang; Aroonrut Lucksiri; J Christopher Gorski; Lang Li; Stephen D Hall
Journal:  Drug Metab Dispos       Date:  2009-11-02       Impact factor: 3.922

3.  Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man.

Authors:  E E Ohnhaus; A M Breckenridge; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.

Authors:  Teddy Kosoglou; Yali Zhu; Fengjuan Xuan; Laura Black; Amy O Johnson-Levonas; Monika Martinho; Paul Statkevich; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2012-04-05       Impact factor: 2.953

Review 5.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 6.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.

Authors:  A Hsu; G R Granneman; G Cao; L Carothers; A Japour; T El-Shourbagy; S Dennis; J Berg; K Erdman; J M Leonard; E Sun
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

9.  Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects.

Authors:  Yuichiro Imamura; Nobuyuki Murayama; Noriko Okudaira; Atsushi Kurihara; Katsuhisa Inoue; Hiroaki Yuasa; Takashi Izumi; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2012-10-17       Impact factor: 4.200

10.  Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.

Authors:  P N Patsalos; J S Duncan; S D Shorvon
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.